Shionogi lands $375M from HHS to develop preventive drug for Covid-19news2025-01-16T20:05:21+00:00January 16th, 2025|Endpoints News|
Moderna lowers 2025 revenue estimate, announces more cost cutsnews2025-01-13T19:43:33+00:00January 13th, 2025|Endpoints News|
Leyden Labs gets $70M to test if nasal sprays can help protect against virusesnews2025-01-09T13:00:32+00:00January 9th, 2025|Endpoints News|
BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royaltiesnews2024-12-27T15:23:42+00:00December 27th, 2024|Endpoints News|
RFK Jr. lobbied against vaccine EUAs. At HHS, he could undo themnews2024-12-11T20:09:11+00:00December 11th, 2024|Endpoints News|
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibbnews2020-11-18T18:00:00+00:00November 18th, 2020|The Catalyst|
Deep dive: The issues that drove the 2020 votenews2020-11-13T17:56:49+00:00November 13th, 2020|The Catalyst|
Understanding the emergency use authorization process for COVID-19 vaccinesnews2020-11-12T14:00:00+00:00November 12th, 2020|The Catalyst|
ICYMI – Addressing health inequities: Biopharmaceutical companies are rising to the occasionnews2020-11-02T19:00:00+00:00November 2nd, 2020|The Catalyst|
U.S. trade policy must prioritize American biopharmaceutical innovation and patient accessnews2020-11-02T18:00:00+00:00November 2nd, 2020|The Catalyst|